Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-06-11Clinical Trial Update: Antibodies to Digoxin for Bipolar Disorder [Phase 2]
A Phase 2 clinical trial testing antibodies against digoxin for Bipolar Disorder has completed, with results to be reported to determine pot…
-
CLINICAL_TRIALS trial_result · 2013-05-30Clinical Trial Update: Indicated Prevention of Psychotic Disorders With Low-dose Lithium [Phase 4]
Phase 4 clinical trial investigating whether low-dose lithium can prevent the onset of psychotic disorders in individuals with schizophrenia…
-
CLINICAL_TRIALS trial_result · 2013-05-29Clinical Trial Update: Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder [Phase 4]
A Phase 4 clinical trial comparing olanzapine and lamotrigine for the prevention of depressive episodes in patients with bipolar disorder ha…
-
CLINICAL_TRIALS trial_result · 2013-05-27Clinical Trial Update: Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder
A completed clinical trial evaluating methods for measuring smoking behavior in individuals with schizophrenia or bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2013-05-22Clinical Trial Update: Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder [Phase 2]
Phase 2 clinical trial evaluating the STIRR intervention for people with co-occurring mental illness and substance use disorders; results we…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-05-21Clinical Trial Update: 12- Week Open Label Treatment of Refractory Bipolar Depression [Phase 4]
A Phase 4 clinical trial update reporting results from a 12-week open-label treatment for refractory bipolar depression; the study is comple…
-
CLINICAL_TRIALS trial_result · 2013-05-10Clinical Trial Update: Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance [Phase 3]
Phase 3 add-on trial of ramelteon for sleep disturbance in bipolar I disorder was terminated.
-
CLINICAL_TRIALS trial_result · 2013-05-06Clinical Trial Update: Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder [Phase 4]
This document reports the completion of a Phase 4 trial comparing risperidone to olanzapine for mania in preschool children aged 4 to 6 with…
-
FDA approval · 2013-04-30FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental NDA for SEROQUEL (quetiapine) filed by H2-Pharma, LLC.
-
FDA approval · 2013-04-30FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for SEROQUEL XR (quetiapine) submitted by AstraZeneca, resulting in changes to the product label…
-
FDA approval · 2013-04-22FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva Pharmaceuticals USA, Inc. to market the olanzapine and fluoxetine combination (OLANZAPINE A…
-
CLINICAL_TRIALS trial_result · 2013-04-16Clinical Trial Update: Sleep Disturbance and Bipolar Disorder [Phase 3]
A Phase 3 trial examining sleep disturbance in bipolar disorder has completed.
-
CLINICAL_TRIALS trial_result · 2013-04-15Clinical Trial Update: Acupuncture as a Supplemental Treatment for Bipolar Depression [Phase 2]
A Phase 2 clinical trial evaluating acupuncture as an adjunctive treatment for bipolar depression has completed.
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability [NA]
This clinical trial evaluated omega-3 fatty acids in bipolar disorder patients with a low omega-3 index and reduced heart rate variability, …
-
CLINICAL_TRIALS trial_result · 2013-04-04Clinical Trial Update: Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine [Phase 4]
Phase 4 trial assessing whether topiramate can prevent olanzapine-associated weight gain in bipolar disorder; results have been posted.
-
CLINICAL_TRIALS trial_result · 2013-04-04Clinical Trial Update: Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital [NA]
Completed clinical trial assessing strategies to reduce the use of unmodified electroconvulsive therapy in an Indian hospital, across major …
-
CLINICAL_TRIALS trial_result · 2013-04-02Clinical Trial Update: Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on) [Phase 3]
A Phase 3 add-on trial of lurasidone for bipolar I depression has completed, with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-03-27Clinical Trial Update: Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents [Phase 3]
Phase 3 trial in children and adolescents with bipolar disorder evaluated the outcomes and safety of lithium, divalproex, and risperidone fo…
-
FDA approval · 2013-03-25FDA Approved: OLANZAPINE AND FLUOXETINE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's olanzapine and fluoxetine combination as an original ANDA generic product for depressive episodes in bipolar I disorder …
-
FDA approval · 2013-03-22FDA Approved: RISPERIDONE — Supplemental Application (Natco Pharma USA LLC)
FDA approved a supplemental application for risperidone from Natco Pharma USA LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2013-03-22Clinical Trial Update: Dental Status of Patients With Severe Mental Illness
Completed clinical trial evaluating dental health status in patients with severe mental illness, including schizophrenia, bipolar disorder, …
-
FDA approval · 2013-03-21FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for SAPHRIS (asenapine). The action approves an updated labeling related to a supplemen…
-
FDA label_change · 2013-03-18FDA Approved: OLANZAPINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for Olanzapine filed by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2013-03-14FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for a generic olanzapine and fluoxetine combination submitted by Par Health USA, LLC. The product is…
-
CLINICAL_TRIALS research · 2013-03-14Clinical Trial Update: A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders [Phase 4]
Phase 4 multicenter study evaluating whether switching from risperidone or paliperidone to aripiprazole improves sexual dysfunction and hype…